EVENT BROCHURE

OPX OLIGOS & PEPTIDES CONFEX 2027 IRELAND EDITION

Oligos & Peptides Confex Ireland 2027

24–25 February 2027

CO-LOCATED EVENTS

BIOLOGICS MANUFACTURING IRELAND 2027

ANTIBODY ENGINEERING & ADC MANUFACTURING IRELAND 2027

OFFICIAL EVENT BROCHURE

https://infohub.imapac.com/oligos-peptides-confex-ireland-2027

Table of Contents

About the Event 3
Agenda at a Glance 4
Agenda 5
Meet the Speakers 11
Our Past Partners 14
Past Partners for the Biologics Manufacturing Ireland & Oligos & Peptides Europe Series 17
Expected Audience Snapshot 19
Targeted Attendees List 20
Sponsorship Packages 22
Sponsorship Opportunities 23
Testimonials 25
Add to Calendar 28
About IMAPAC 29

EVENT HIGHLIGHTS

150+	60+	20+
ATTENDEES	COMPANIES	EXPERT SPEAKERS

DATE & VENUE

24–25 February 2027

Dublin
Ireland

CO-LOCATED EVENTS

BIOLOGICS MANUFACTURING IRELAND 2027

ANTIBODY ENGINEERING & ADC MANUFACTURING

About the Event

Europe's leading end-to-end forum for oligonucleotides and peptides, bringing together 200+ leaders in Dublin to advance these modalities from Discovery and Innovation through to Scale and Commercialisation.

WHO / WHAT / WHY

WHO

200+ leaders across oligonucleotide and peptide discovery, development, CMC, manufacturing and commercialisation.

WHAT

Europe's end-to-end forum taking oligonucleotide and peptide therapeutics from Discovery & Innovation to Scale & Commercialisation.

WHY

Explore the latest advances in synthesis, analytics, formulation, manufacturing and scale-up — while building connections across the value chain.

WHAT TO EXPECT

150+
Decision Makers

20+
Expert Speakers

60+
Companies Represented

FEATURED TESTIMONIAL

"I had the pleasure of collaborating with the IMAPAC team during the Irish leg of the Biologics World event in February 2026. The organisers were exceptionally receptive and helpful, ensuring a seamless experience throughout the planning, exhibition logistics, partnering sessions, and sponsor visibility. Their proactive approach in connecting us with potential partners significantly enhanced our ROI. We are already exploring future opportunities to work with the IMAPAC team."

Terry Gray · Field Marketing Manager · Merck

Agenda at a Glance

DAY 1 | 24 FEBRUARY 2027	DAY 2 | 25 FEBRUARY 2027
Ireland's Peptides & Oligonucleotides Industry	CMC, Regulatory & Quality-by-Design Strategy
NETWORKING BREAK	
Analytical Characterisation & Quality Control	Supply Chain Resilience & Capacity Strategy
LUNCH	
Manufacturing & Process Development	Smart Aseptic Fill-Finish
NETWORKING BREAK	
Roundtable Session: Advancing Peptide & Oligonucleotide Development	Shaping the Future: Of Peptide & Oligonucleotide
END OF CONFERENCE DAY 1	END OF CONFERENCE

Day 1

24 February 2027

08:30 **Registration & Coffee**

08:55

Chairman's Welcome Address

Nikki Toms
Global Head ADC, AstraZeneca, UK

Ireland's Peptides & Oligonucleotides Industry: Innovation, Resilience and Digitalisation

09:00

Driving Innovation in Peptide & Oligonucleotide Manufacturing in Ireland

- Emerging technologies in synthesis, purification, and analytics
- Process intensification strategies for higher yield and efficiency
- Leveraging Ireland's manufacturing ecosystem for collaborative R&D
- Case studies of recent innovations in oligo and peptide production

09:25 **Reserved for Solution Provider**

09:50

PANEL DISCUSSION

Leading the Future of Peptide and Oligonucleotide Manufacturing: Strategies for Resilience, Digital Transformation, and Innovation in Ireland

- Leadership perspectives on driving digital adoption across manufacturing and supply chains
- Strategic approaches to enhance operational resilience and risk mitigation
- Collaborations between industry, academia, and CDMOs to accelerate innovation
- Balancing regulatory compliance, process efficiency, and scalable manufacturing

10:15 **Networking Break**

Day 1

24 February 2027

Analytical Characterisation & Quality Control

11:00

Advanced Analytical Techniques for Peptide & Oligonucleotide Therapeutics

- Implementation of high-resolution methods such as LC-MS and HPLC for complex molecules
- Detecting and controlling impurities, modifications, and degradation products
- Optimising sample preparation and method sensitivity for challenging therapeutics
- Ensuring analytical comparability across clinical and commercial batches

11:25

Reserved for Solution Provider

11:50

Using Statistical Modelling to Improve Stability Prediction and CMC Decision-Making

Dr Warren Roche
Senior Biostatistician Expert, Argenx, Belgium

12:15

Lunch

Oligonucleotide & Peptide Manufacturing and Process Development

13:15

Building the ADAR Chemistry Toolbox: Engineering the Phosphorus Backbone with Safer Chemistries for Next-Generation ASOs

Juergen Mueller
Head of Chemistry & Managing Director, AIRNA, Switzerland

14:00

Reserved for Solution Provider

Day 1

24 February 2027

14:25

Optimising Downstream Process Development for Scalable and Robust ASO Manufacturing

Armin Delavari
Senior Scientist, Technical Development, Biogen, USA

14:50 — **Networking Break**

15:30

ROUNDTABLE DISCUSSION

1. How Cross-Industry Collaboration is Accelerating Innovation and Driving Growth in Peptide and Oligonucleotide Manufacturing
2. Identifying Emerging Trends and Opportunities to Shape the Future of Oligos & Peptides
3. Enhancing Cross-Functional Collaboration Across Manufacturing Teams
4. Driving Operational Excellence and Innovation Through Industry Collaboration
5. Topic: TBC
   Sunay Chankeshwara — Associate Principal Scientist, AstraZeneca, Sweden
6. Topic: TBC
   Barbara Barbosa — Global Medical Director, Vicore Pharma AB, Switzerland

16:30 — **Key Takeaways**

16:45 — **END OF CONFERENCE DAY 1**

Day 2

25 February 2027

08:30 **Registration & Coffee**

08:55

Chairman's Welcome Address

Nikki Toms
Global Head ADC, AstraZeneca, UK

CMC, Regulatory & Quality-by-Design Strategy

09:00

Applying MSAT Principles to Accelerate CMC Readiness and Commercial Manufacturing of Complex Injectable Therapies

Dr Dikshitkumar Khamar
Senior Director, Head of Scientific Excellence, MSAT Injectables, Sanofi, Ireland

09:25 **Reserved for Solution Provider**

09:50

Applying Quality-by-Design Principles to Optimise Manufacturing and Product Consistency

- Embedding QbD from early development to commercial scale
- Ensuring reproducibility and comparability across sites
- Preparing for regulatory inspections and approvals
- Cross-functional collaboration for continuous improvement

10:15 **Networking Break**

Supply Chain Resilience & Capacity Strategy

Day 2

25 February 2027

10:45

From Risk Management to Operational Resilience: Designing Successful Commercial Launches

- Designing resilient operating models, not just compliant processes
- Identifying risks before they become operational disruptions
- Eliminating critical dependencies and single points of failure across the value chain
- Balancing resilience, agility and commercial readiness to ensure successful product launches

Peter Coughlan
Associate Director - Supply Chain Risk Management, Alkermes, Ireland

11:10

11:35

Reserved for Solution Provider

12:00

PANEL DISCUSSION

Capacity Planning and Operational Excellence to Maximise Throughput and Reliability

- Aligning production planning with pipeline growth
- Resource and workforce allocation strategies
- Ensuring consistent quality across multiple sites
- Lessons from real-world capacity challenges and solutions

12:40

Lunch

Smart Aseptic Fill-Finish

13:40

Implementing Automation and Advanced Technologies to Achieve Efficient and Reliable Aseptic fill-finish Operations

- Integration of robotics and automated systems for consistent production
- Reducing contamination risk and human error in sterile processes
- Streamlining workflows to maximise throughput and flexibility
- Case studies demonstrating successful automation adoption

Day 2

25 February 2027

13:25 — **Reserved for Solution Provider**

14:05 — **Reserved for Solution Provider**

14:30

Enhancing Quality, Reliability, and Operational Performance Through Data-Driven Fill-Finish Strategies

- Real-time monitoring and predictive maintenance using PAT
- Integrating upstream and downstream processes for operational efficiency
- Maintaining sterility and regulatory compliance
- Operational lessons from commercial-scale implementation

14:55 — **Networking Break**

Shaping the Future: Of Peptide & Oligonucleotide

15:15

Advancing Oligonucleotide Chemistry from Development to Scalable Drug Substance Manufacturing

Peter D Smith
Director, New Modalities Chemistry, AstraZeneca, UK

15:40

Strategic Innovations Driving Peptide & Oligonucleotide Manufacturing in Ireland

- Emerging technologies shaping manufacturing workflows and process efficiencies
- Leveraging Ireland's biopharma ecosystem for collaboration and innovation
- Optimising scale-up strategies from clinical to commercial production
- Integrating digitalisation and process analytics to improve throughput and quality

16:05 — **Chairman's Closing Remarks**

16:10 — **END OF CONFERENCE**

MEET THE SPEAKERS



Sunay Chankeshwara
Senior Peptide Expert (Associate Principal Scientist)
AstraZeneca
SWEDEN

Armin Delavari
Senior Scientist, Technical Development
Biogen
US

Peter Coughlan
Associate Director - Supply Chain Risk Management
Alkermes
IRELAND

Ann De Saeger
Principal Scientist II
J&J Innovative Medicine
BELGIUM



Juergen Mueller
Head of Chemistry & Managing Director
AIRNA
SWITZERLAND



Dr Dikshitkumar Khamar
Senior Director, Head of Scientific Excellence, MSAT Injectables
Sanofi
IRELAND



Peter D Smith
Director, New Modalities Chemistry
AstraZeneca
UK



Barbara Barbosa
Global Medical Director
Vicore Pharma AB
SWITZERLAND



Dr Warren Roche
Senior Biostatistician Expert
Argenx
BELGIUM



Nadim Akhtar
Senior Principal Scientist New Modalities
AstraZeneca
UK

BIOLOGICS MANUFACTURING IRELAND 2027



Timmy Carey
Director of Global Environmental Sustainability
BioMarin
IRELAND



Miriam O'Sullivan
Executive Director Plant Manager
Amgen
IRELAND



Declan Lowney
Director of Stability Sciences, BioTherapeutics Development Analytical Development
J&J
IRELAND



Cian O'Brien
Site Head
Sanofi
IRELAND



Reinaldo Rivera
Director Regulatory CMC
Amgen
IRELAND



Sara Moscetti
Senior Technical Leader, CMC Director
Chiesi Group
IRELAND



Áine Fleming
VP, Head of Engineering Speciality Care
Sanofi
IRELAND



Anne Marie Molloy
Associate Director Upstream Manufacturing Science and Technology
BMS
IRELAND



Keith Coleman
Director - CMC Strategy
BMS
IRELAND



Gillian Fitzpatrick
Director QA Operations
MSD
IRELAND



Darrin Morrissey
CEO
NIBRT
IRELAND

FO

Fionnuala O'Driscoll
Executive Director of Global Regulatory Affairs - CMC
Eli Lilly and Company
IRELAND



Harsha Reddy
Group Lead - Head Upstream Process Development, CMC Bioprocess Lead
Accord BioPharma
UK



CHAIRMAN

Brendan Noone
Senior Director, Global Supply Chain & Strategy
AstraZeneca
IRELAND

ANTIBODY ENGINEERING & ADC MANUFACTURING IRELAND 2027



Michael Hackebeil
Senior Scientist Drug Development
CIS Biopharma AG
SWITZERLAND

DH

Dr. Christian Hunzinger
Executive Director Global Process and Analytical Development Proteins, ADCs and Chemical Entities
BioNtech SE
GERMANY



Sharon Fitzgerald
Senior Manager, Manufacturing Technology
BMS
IRELAND



Barry Tangney
Principal Scientist, Manufacturing Technology
BMS
IRELAND



Nikki Toms
Global Head ADC
AstraZeneca
UK



Kacey Fetcho-Phillips
AVP Site Head
MSD
IRELAND



Matthew Lambert
Senior Director
Pfizer
IRELAND



Paul Kellam
CSO and co-founder
RQ Biotechnology
UK



Mairead Looby
Executive Director, Bio S&T Technical Operations DS
MSD
USA



Suzanne Randle
Associate Director in Oncology Safety Science
AstraZeneca
UK



Philipp Ellinger
Senior Principal Scientist, Senior Science Fellow-Therapeutic Antibodies Cluster
Bayer
GERMANY



Cathal Gallagher
Senior Director-Head of Quality, External Operations EU
Takeda
IRELAND



Prof. Nicki Panoskaltsis
Professor and Chair of Personalised Therapeutics
Trinity College Dublin
IRELAND



Jay Zhao
Chief Technology Officer and Co-founder
Kali Therapeutics
USA



Guglielmo Iozzia
Director, ML/AI and Applied Mathematics
MSD
IRELAND



Debra Nevin
Head Of CMC
RQ Biotechnology
UK



Brian Fennell
eam Leader for Antibody Discovery and Optimisation
Pfizer
IRELAND



Sarah Pasqualinotto
External Site Lead, External Operations (Associate Director)
Biogen
SWITZERLAND

Our Past Partners



Our Past Partners (cont.)



Our Past Partners (cont.)



Past Partners for the Biologics Manufacturing Ireland & Oligos & Peptides Europe Series

Past Partners for the Biologics Manufacturing Ireland & Oligos & Peptides Europe Series (cont.)

Expected Audience Snapshot

80%
BIOPHARMA & BIG PHARMA

20%
SERVICE & SOLUTION PROVIDERS

BY PROFILE

Large Pharma & Biopharma Manufacturers	50%
Emerging / Specialty Biotech	50%

BY SENIORITY

Director	42%
Head of Department	22%
VP	17%
Senior Director	11%
Associate Director	8%

BY JOB TITLE

Manufacturing & Operations	16%
Process Development	16%
CMC Development	11%
MSAT & Manufacturing Sciences	11%
Analytical Sciences	8%
Drug Product / Substance Development	8%
Technical Operations	8%
Quality, Compliance & Regulatory CMC	8%
Pharmaceutical Development	5%
API Development	3%
Supply Chain & External Manufacturing	3%
Technology Transfer	3%

DECISION MAKERS

Decision Makers	100%

BY GEOGRAPHY



Targeted Attendees List

Companies and senior roles represented across the selected event(s)

Oligos & Peptides Confex Ireland 2027

JOB TITLE	COMPANY	COUNTRY
Job Title	Company	Country
Director, Technical Operations	Autolus Therapeutics	United Kingdom
Senior Director, Pharmaceutical Development	Autolus Therapeutics	United Kingdom
Director, Manufacturing Sciences & Technology	Bicycle Therapeutics	United Kingdom
VP, Head of Oligonucleotide Manufacturing	Jazz Pharmaceuticals	Ireland
VP, Head of Peptide Manufacturing	UCB	United Kingdom
Director, Regulatory CMC	AstraZeneca	United Kingdom
Director, Process Development	Regeneron	Ireland
Senior Director, CMC	Johnson & Johnson	Ireland
Head of Technical Operations	Autolus Therapeutics	United Kingdom
VP, Head of Oligonucleotide Manufacturing	AstraZeneca	United Kingdom
Senior Director, CMC	Adaptimmune	United Kingdom
Director, Analytical Sciences	Immunocore	United Kingdom
Head of Analytical Development	Pfizer	Ireland
Senior Director, MSAT	Pfizer	Ireland
Director, Oligonucleotide Process Development	BenevolentAI	United Kingdom
Director, API Development	AbbVie	Ireland
VP, Head of Peptide Manufacturing	GSK	United Kingdom
Director, Drug Product Development	BenevolentAI	United Kingdom
Director, Technical Operations	Autolus Therapeutics	United Kingdom
Senior Director, Pharmaceutical Development	Autolus Therapeutics	United Kingdom

Targeted Attendees List (cont.)

Oligos & Peptides Confex Ireland 2027

JOB TITLE	COMPANY	COUNTRY
Director, Manufacturing Sciences & Technology	Bicycle Therapeutics	United Kingdom
VP, Head of Oligonucleotide Manufacturing	Jazz Pharmaceuticals	Ireland
VP, Head of Peptide Manufacturing	UCB	United Kingdom
Director, Regulatory CMC	AstraZeneca	United Kingdom
Director, Process Development	Regeneron	Ireland
Senior Director, CMC	Johnson & Johnson	Ireland
Head of Technical Operations	Autolus Therapeutics	United Kingdom
VP, Head of Oligonucleotide Manufacturing	AstraZeneca	United Kingdom
Senior Director, CMC	Adaptimmune	United Kingdom
Director, Analytical Sciences	Immunocore	United Kingdom
Head of Analytical Development	Pfizer	Ireland
Senior Director, MSAT	Pfizer	Ireland
Director, Oligonucleotide Process Development	BenevolentAI	United Kingdom
Director, API Development	AbbVie	Ireland
VP, Head of Peptide Manufacturing	GSK	United Kingdom
Director, Drug Product Development	BenevolentAI	United Kingdom

VIEW THE FULL ATTENDEE LIST →

Sponsorship Opportunities

Sponsorship Packages

DIAMOND

PACKAGE INCLUDES

- Full-day workshop for 30 pax: room, lunch, 2 refreshment breaks, coffee / tea
- Keynote solo presentation: 20 min + 5 min Q&A
- 25-minute end-user client case study
- 12 sqm exhibition space (4×3m booth + banner)
- 1 speaker pass; 7 guest passes; 2 exhibitor passes
- 10 onsite 1:1 meetings
- Lead retrieval

PLATINUM

PACKAGE INCLUDES

- Half-day workshop for 30 pax: room, 1 refreshment break, coffee / tea
- Prime-billing solo presentation: 20 min + 5 min Q&A
- 25-minute end-user client case study
- 12 sqm exhibition space (4×3m booth + banner)
- 1 speaker pass; 7 guest passes; 2 exhibitor passes
- 10 onsite 1:1 meetings
- Lead retrieval

GOLD

PACKAGE INCLUDES

- Prime-billing solo presentation: 20 min + 5 min Q&A
- 9 sqm exhibition space (3×3m booth + banner)
- 1 speaker pass; 5 guest passes; 2 exhibitor passes
- 10 onsite 1:1 meetings
- Lead retrieval

SILVER (ENHANCED)

PACKAGE INCLUDES

- Solo presentation: 20 min + 5 min Q&A
- 6 sqm exhibition space (3×2m booth + banner)
- 1 speaker pass; 3 guest passes; 2 exhibitor passes
- 5 onsite 1:1 meetings
- Lead retrieval

SILVER

PACKAGE INCLUDES

- Solo presentation: 10 min + 5 min Q&A
- 6 sqm exhibition space (3×2m booth + tabletop display)
- 1 speaker pass; 2 guest passes; 2 exhibitor passes
- 5 onsite 1:1 meetings
- Lead retrieval

BRONZE

PACKAGE INCLUDES

- Solo presentation: 10 min + 5 min Q&A
- 6 sqm exhibition space (3×2m booth)
- 1 speaker pass; 2 guest passes
- Lead retrieval

EXHIBITION + 10 MEETINGS

PACKAGE INCLUDES

- 6 sqm exhibition space (3×2m booth + banner)
- 1 guest pass; 2 exhibition passes
- 10 onsite 1:1 meetings
- Lead retrieval

EXHIBITION + 5 MEETINGS

PACKAGE INCLUDES

- 6 sqm exhibition space (3×2m booth + banner)
- 1 guest pass; 2 exhibition passes
- 5 onsite 1:1 meetings
- Lead retrieval

EXHIBITION

PACKAGE INCLUDES

- 6 sqm exhibition space (3×2m booth + banner)
- 1 guest pass; 2 exhibition passes
- Lead retrieval

Sponsorship Opportunities

Who Should Sponsor?

- Peptide Synthesis Platforms
- Lipid Nanoparticle (LNP) Formulation Providers
- Purification & Chromatography Technologies
- Automation & Robotics Providers
- Linker & Conjugation Technology
- Toxicology & Bioanalytical Service Providers
- Analytical & Characterisation Solutions
- Solid-Phase & Flow Chemistry Systems
- Regulatory & Quality Software Providers
- Oligonucleotide Synthesis Technology
- Drug Delivery Systems
- Bioprocessing Equipment
- Microfluidics & Continuous Manufacturing Systems
- HPLC, LC–MS, & Spectroscopy Systems
- Clinical Trial Logistics & Cold Chain Partners
- Automated Synthesisers
- Bioinformatics & AI Tools
- Nanotechnology & Targeted Delivery Platforms
- mRNA & RNA Therapeutics Platforms
- Peptide & Oligo Design Software
- Single-Use Manufacturing Solutions
- Cryopreservation & Storage Solutions
- Packaging & Delivery Device Innovators
- Raw Material & Reagent Suppliers
- CROs & CMOs
- Stability Testing & Formulation Experts

Why Sponsor

SPONSORSHIP BENEFITS

- Thought Leadership Speaking
- Panel Participation
- Solution Showcases
- Engagement and Visibility Opportunities
- Branding and Digital Visibility
- Exclusive Networking

TESTIMONIALS

The Biologics and CGT Manufacturing DACH conference 2026 was very well planned and coordinated. It provided high-quality talks for staying up-to-date in our industry and I specifically enjoyed the time for networking.



Dr Heiner Apeler
VP Head of Biologics Development
Bayer
GERMANY

Thanks for the invite to speak at the event. It was a really enjoyable meeting and a great opportunity to present our work to the community. Identifying key partners for ImmunoKey's development plan is a critical aspect of getting our therapies to patients; the CGT and Biologics Manufacturing DACH meeting offered us the opportunity to engage with key CDMOs who can help us achieve this goal.



John Bridgeman
CSO
Immunokey
UK

Just back from an incredible time at the Biologics Manufacturing DACH congress! I have to be honest - as someone in Procurement, some of the deep-dives into Cell & Gene and biologics development were definitely above my scientific capabilities! However, the exchange of knowledge was fantastic, and it was a privilege to learn from such brilliant minds. A true highlight was the fantastic collaboration with Christopher Pawlak (PhD) . I had the privilege of co-hosting a round table with him focused on the impact of tariffs in the biopharma world. Christoph, thank you for the partnership - it was a truly dynamic discussion! 🤝 One of my biggest takeaways is that we have officially entered the era of "The Great Reshoring". We are moving past the days when drug manufacturing decisions were purely scientific; they are now deeply geopolitical. As we discussed in our round table, we can no longer just react to change. We have to treat scenario planning like a muscle that we train constantly to design for volatility. The event really hit home how much our world is changing - from the incredible progress in biologics manufacturing to the AI evolution. I'm excited to see how we can implement these insights to build resilience and benefit BMS biologics manufacturing. Back to my desk, I will start with socializing the learnings with my colleagues. A huge thank you to Drishti G. for the flawless organization and to Noel Murphy for approving the trip and supporting this critical learning opportunity!



Dennis Stelljes
Associate Director, Strategic Sourcing & Procurement, Biologics External Manufacturing
BMS
SWITZERLAND

TESTIMONIALS (cont.)

Really well organised conference with great attendees and high engagement - I was delighted to have taken the time to attend and really enjoyed sharing my thoughts on Accelerating Biologics Pipeline and ensuing discussion. Thank you to all organisers and facilitators



Dr Andrew Kelly
Director, Manufacturing Technology
BMS
IRELAND

A fantastic deep dive into the DACH region's CGT landscape. This conference made one thing clear: efficacy is proven, but industrialization is the new frontier. To truly move the needle, we must look beyond the lab and focus on scaling automation, streamlining supply chains, and tackling COGS. The diversity of voices - from large corporations, to tech suppliers and academic pioneers - provided a 360-degree view of the manufacturing challenges we must solve together.



Dr Thomas Villiger
Professor of Bioprocess Technology
University of Applied Sciences and Arts Northwestern Switzerland FHNW
SWITZERLAND

Thanks for the invite. The conference was really excellent, due to the caliber and engagement of the attendees.



Brian O'Connor
VP Global Quality
Orchard Therapeutics
UK

Thanks for putting this together! I enjoyed the discussions, atmosphere and engagement of participants. Great to be there!



Alvaro Avivar-Valderas
Associate Director - Cell Therapy Technology & Product Engine
Takeda
SPAIN

TESTIMONIALS (cont.)

I thoroughly enjoyed attending the CGT Manufacturing DACH 2026 by IMAPAC. The program featured exceptionally industry-relevant talks that provided deep insights into the current landscape. Beyond the sessions, the networking opportunities were top-tier, thanks to the high caliber of participants.



Steffen Schulze
Strategic Analytics & Business Analytics Lead
Roche
SWITZERLAND

I had the pleasure of collaborating with the IMAPAC team during the Irish leg of the Biologics World event in February 2026. The organisers were exceptionally receptive and helpful, ensuring a seamless experience throughout the planning, exhibition logistics, partnering sessions, and sponsor visibility. Their proactive approach in connecting us with potential partners significantly enhanced our ROI. We are already exploring future opportunities to work with the IMAPAC team.

Terry Gray
Field Marketing Manager
Merck

Thank you for your email and organising this wonderful event. It was a pleasure to participate. Congratulations on organising this event. It was a wonderful opportunity to present our work and to collaborate with others in the area. Looking forward to your next event



Warren Roche
Senior Statistical Expert
Sanofi
IRELAND

Thank you, it was a pleasure meeting you, and your enthusiasm made it an engaging and positive event. I hope we have opportunity to connect again in the future.



Michael Inglis
Head of Manufacturing Sciences, Analytical Technologies
Chiesi Farmaceutici Global Rare Disease
IRELAND

Well done on a very informative and successful event.



Shada Warreth
Global Partnerships Implementation Senior Manager
NIBRT
IRELAND

MARK YOUR CALENDAR

Save the Date

24–25 FEB 2027 Dublin

Oligos & Peptides Confex Ireland 2027

ALL IMAPAC EVENTS

Explore Our Full Event Calendar

Discover upcoming IMAPAC biopharmaceutical conferences, summits, and exhibitions across Europe and worldwide. →

OR ADD THIS EVENT TO YOUR CALENDAR

Google Calendar
One-click add to Gmail →

Outlook Calendar
Add to Microsoft Outlook →

Scan to Register

Open camera, point at code, instant registration access.

Or click the QR to open registration directly.

A VARIETY OF PRODUCTS TO CATER TO GLOBAL BIOPHARMACEUTICAL INDUSTRY'S MARKET INTELLIGENCE AND BUSINESS CONNECTIONS NEEDS.

01 B2B EVENTS

Thought-leadership, industry knowledge-sharing and quality networking are at the core of IMAPAC's B2B events.

Create an engaging experience for your audiences, explore our B2B Events Solutions.

02 360 MARKETING SOLUTIONS

Expand your reach and influence! Be it with customized events, digital marketing solutions, content creation or thought-leadership.

Tap into our global audience spanning the sub-sectors and regions shaping the biopharmaceutical industry.

03 DASHBOARDS

A quick-view analytics tool to power your decisions. Access region or country-specific data to uncover pipeline information, product focus.

Customize the dashboard based on your needs. Drill down to the data you need using custom views.

04 CUSTOM RESEARCH

Based on your objectives and budget, you can customize a package to one that best meets your intelligence needs. This allows you to maximize your ROI without spending on items that are not in line with your strategies.

With access to a database of 60,000+ life science professionals. We conduct research with a highly-qualified audience.

05 REPORTS

Discover in-depth market information of the growing biopharmaceutical sector.

Learn More →

HELPING THE GLOBAL BIOPHARMACEUTICAL INDUSTRY

Generate Tangible Growth

IMAPAC is the one-stop shop of market intelligence and business connections for the global biopharmaceutical industry. We help companies expand their influence, make data driven decisions through our industry intelligence, and link up with other biopharmaceutical professionals to exchange knowledge and engage in quality networking. At the core of IMAPAC is our mission to help biopharmaceutical businesses globally generate tangible growth. At the same time, our heart lies in giving back to society. We empower the next generation by equipping underprivileged children with an education.

WEBSITE
imapac.com

EMAIL
info@imapac.com

IMAPAC PTE LTD
36 Robinson Road, #02-01
Singapore 068877
+65 6983 6140

IMAPAC UK LTD
77 Farringdon Road, Farringdon
London EC1M 3JU, United Kingdom
+44 161 552 8507

CONNECT WITH US

LINKEDIN
@imapac

X
@imapac

FACEBOOK
ImapacPteLtd